Clinical trials: Hydrocortisone
Atopic Dermatitis
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
This randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of lebrikizumab administered subcutaneously (SC) in adult participants with persistent moderate to severe atopic dermatitis (AD) who…
- Trial name
- NCT02340234
- Testing
- Lebrikizumab, TCS Cream
- Where
- 74 sites in United States, Australia and 12 more
- Volunteers
- 212 people
- Sponsor
- Hoffmann-La Roche
Acute Myeloid Leukemia
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it…
- Trial name
- NCT03793478
- Testing
- Quizartinib, Fludarabine, Cytarabine
- Where
- 27 sites in United States, Belgium and 8 more
- Volunteers
- 65 people
- Sponsor
- Daiichi Sankyo
Cushing's Disease
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease.
- Trial name
- NCT01374906
- Testing
- pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg
- Where
- 82 sites in United States, Argentina and 18 more
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Hypercortisolism
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with…
- Trial name
- GRADIENT (NCT04308590)
- Testing
- Relacorilant
- Where
- 45 sites in United States, Austria and 7 more
- Volunteers
- 137 people
- Sponsor
- Corcept Therapeutics
Asthma
A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands
The medications being used in this study are individually approved by the Food and Drug Administration (FDA). The medication under investigation is a combination of the two medications in one inhaler.
- Trial name
- NCT00657774
- Testing
- FlutiForm 250/10 ug, FlutiForm 100/10 ug, Oral Prednisone 10mg
- Where
- 19 sites in United States
- Volunteers
- 160 people
- Sponsor
- SkyePharma AG
Cushing's Syndrome
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
This is an observational study to confirm the presence of recurrent or persistent endogenous Cushing's syndrome in patients who have had primary surgical and/or radiation therapy for Cushing's disease and continue to manifest…
- Trial name
- NCT00796783
- Testing
- Cushing's syndrome confirmation
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Corcept Therapeutics
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
This is a Phase I/II, multicenter, open-label, multi-arm study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin, administered as a single agent or in combination with…
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
- Trial name
- NCT04029688
- Testing
- Idasanutlin, Venetoclax, Cyclophosphamide
- Where
- 14 sites in United States, Canada and 4 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.
- Trial name
- NCT00623766
- Testing
- Ipilimumab, Corticosteroid: Betamethasone, Corticosteroid: Dexamethasone
- Where
- 14 sites in United States
- Volunteers
- 99 people
- Sponsor
- Bristol-Myers Squibb
Healthy Adult Male Volunteers
Evaluation of Systemic Bioavailability and Effects on 24-Hour Plasma Cortisol Profile of 6 mg Delivered Once Daily Versus 3 mg Delivered Twice Daily in Healthy Adult Male Volunteers
Single-centre, randomized, double-blind, two-period, two-sequence, cross-over 7-day study. This study is the first safety/tolerability evaluation of a product -suppository formulation containing 6 mg BDP (once daily dosing), a…
- Trial name
- NCT04873063
- Testing
- Beclomethasone dipropionate
- Where
- Italy
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- SOFAR S.p.A.
Stress, Mood
Effect of Black Cumin Seed Oil Supplementation on Cortisol, Stress and Mood
The primary objective of this study will be to collect data to support the role of black cumin seed oil, also known as black seed oil (BSO), in moderating the stress response, including objective markers of stress (cortisol/DHEA)…
- Trial name
- NCT06950424
- Testing
- black cumin seed oil
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shawn Talbott
Internal Hemorrhoids
Safety and Efficacy Study of Anucort HC TM 25mg Rectal Suppositories to Treat Symptomatic Internal Hemorrhoids
The primary objective of this study is to determine the safety and efficacy of G\&W Laboratories' Anucort HC TM (Hydrocortisone Acetate) 25mg Rectal Suppositories in subjects with internal hemorrhoidal symptoms.
- Trial name
- NCT01913158
- Testing
- Anucort-HC, 25 Mg Rectal Suppository
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- G & W Laboratories Inc.
Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
The primary objectives of this study are to evaluate the safety and tolerability of opevesostat in the treatment of male Chinese participants with metastatic castration-resistant prostate cancer (mCRPC) and to characterize the…
- Trial name
- NCT06136598
- Testing
- Opevesostat, Dexamethasone, Fludrocortisone
- Where
- 3 sites in China
- Volunteers
- 14 people
- Sponsor
- Merck Sharp & Dohme LLC
Cushing's Syndrome
Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion
This study will evaluate whether the drug mifepristone can improve the symptoms of Cushing's syndrome in people with ectopic adrenal corticotrophin hormone (ACTH) secretion.
- Trial name
- NCT00422201
- Testing
- Mifepristone
- Where
- 15 sites in United States, France and 3 more
- Volunteers
- 18 people
- Sponsor
- HRA Pharma
Root Canal Obturation
Endodontic Post-operative Pain Evaluation of Patients After Using Endomethasone N or Endomethasone SP (EndoPOP)
The study is a post-marketing performance and safety study, designed as a comparative, prospective, multicenter, simple-blind, randomized clinical trial.
- Trial name
- EndoPOP (NCT04885686)
- Testing
- Endomethasone N RCS, Endomethasone SP RCS
- Where
- 15 sites in France
- Volunteers
- 300 people
- Sponsor
- Septodont
Prostate Cancer, Prostate Adenocarcinoma
Trilostane for Androgen-Independent Prostate Cancer
The main purpose of this study is to test the safety of trilostane by looking at what effects, good and bad, it has on patients with androgen-independent prostate cancer.
- Trial name
- NCT00181597
- Testing
- Trilostane, Hydrocortisone
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genzyme, a Sanofi Company
Menopause
A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women
This study compares the effects of 12 weeks of treatment with transdermal versus oral estrogen therapy on testsoterone levels and thyroid tests in healthy, naturally menopausal women.
- Trial name
- NCT00224094
- Testing
- Premarin® (oral) vs. Alora® (transdermal)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Watson Pharmaceuticals
Cushing's Syndrome
Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome
The purpose of this prospective, international phase III/IV study is to assess the efficacy and safety of metyrapone in patients with endogenous Cushing's syndrome during up to 36 weeks of treatment.
- Trial name
- PROMPT (NCT02297945)
- Testing
- metyrapone
- Where
- 36 sites in Belgium, Germany and 6 more
- Volunteers
- 50 people
- Sponsor
- HRA Pharma
Otitis Externa
A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension
The objective of this study is to compare the efficacy and safety profiles of the test product containing 2 mg/mL ciprofloxacin hydrochloride associated with 10 mg/mL of hydrocortisone with the reference product Cipro HC®, in…
- Trial name
- NCT00980876
- Testing
- Cipro HC, Ciprofloxacin HCl and Hydrocortisone
- Where
- Brazil
- Volunteers
- 224 people
- Sponsor
- Farmoquimica S.A.
Atopic Dermatitis
Sinecort Pilot Efficacy Study
The study shall prove whether treatment of atopic dermatitis is equally effective with Sinecort cream as compared to standard therapy (Hydrocortisone cream).
- Trial name
- Sinecort Pilot (NCT00980135)
- Testing
- Sinecort cream, Hydrocortison cream, Untreated skin
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Bayer
Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL)
A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
This study is about an anticancer drug called ponatinib which is a tyrosine kinase inhibitor given with chemotherapy to children, teenagers, and young adults up to 21 years of age with Philadelphia Chromosome-Positive Acute…
- Conditions
- Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)
- Trial name
- NCT04501614
- Testing
- Ponatinib, Chemotherapy Agents
- Where
- 64 sites in United States, Argentina and 13 more
- Volunteers
- 11 people
- Sponsor
- Takeda